Novartis' Alcon received CE mark approval to sell its AcrySof IQ PanOptix trifocal intraocular lens in Europe. The implantable lens corrects near, intermediate and distance vision in cataract patients.
After last week's expert panel meetings, the FDA may put some label limits on PCSK9 cholesterol drugs. But if word from doctor surveys is any indication, those limits won't put a huge damper on sales.
Two months ago, the FDA issued a warning letter for a Hospira plant in Italy noting a number of problems including its lack of controls for access to prevent data deletions from test equipment. Health Canada has decided that issue is enough for it to ban products coming out of the sterile manufacturing facility.
The deputy head of China's State Administration for Industry and Commerce has been arrested for corruption, putting an agency that was at the center of the GlaxoSmithKline bribery probe into its own spotlight.
China has moved to flesh out guidelines for an expansion of private hospitals by allowing subsidies and finance to flow to new companies as a way to allow patients access to newer services and ease demand on the public system.
Genea Biomedx partnered its three fertility products in development with Merck KGaA last month. Now it's won a CE mark for two of them: the Gavi automated vitrification instrument and the Geri benchtop incubator.
Accurexa believes it has the makings for better brain surgery with its therapeutic delivery device BranchPoint. The company has submitted it to the FDA for 510(k) clearance; it allows for the insertion of therapeutics, such as stem cells or oncology drugs, to multiple sites in the brain via a single penetration point with the radial deployment of a flexible catheter.
When any member of the European Union finds issue with a drugmaker, it is reported to a central database to alert other members that might also buy from that facility. Now Slovenia has raised red flags about an Indian drugmaker it says it discovered during an inspection is not meeting cGMP standards.
PatientsLikeMe teamed up with U.S. regulators on a safety-monitoring project, hoping to pinpoint a new med's risks and benefits sooner than the FDA's current surveillance program does.
In late 2013, Jubilant Life Sciences ran into trouble with the FDA over problems at its Jubilant HollisterStier sterile manufacturing plant in Spokane, WA, which the agency considered serious enough that it issued a warning letter. But after 18 months of work, the Indian company said the FDA has upgraded the plant's standing.